Pluri Inc.
PLUR evidence brief
What we can confirm
- BioSniper Score:
- 3.1 / 10
- Market Cap:
- $14.6M
- Lead Asset:
- plx-r18 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for PLUR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLUR
Pluri Inc. is a biotechnology company leveraging a proprietary 3D cell-expansion platform to develop cell-based products across human health, longevity, and foodtech, with a lead pipeline candidate in Phase 1 for hematopoietic indications.
Key risk: Cash runway risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$14.6M
Cash Runway
—
Lead Asset
plx-r18 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Pluri Inc..
Pluri Inc. is a biotechnology company leveraging a proprietary 3D cell-expansion platform to develop cell-based products across human health, longevity, and foodtech, with a lead pipeline candidate in Phase 1 for hematopoietic indications.
- Pluri's proprietary 3D cell-expansion platform is supported by an in-house, industrial-scale GMP manufacturing facility [sec_mda · as of 2026-09-10].
- Lead pipeline candidate PLX-R18 (fetal mesenchymal stromal cell-like cells) is in Phase 1 for incomplete recovery following HCT and H-ARS, developed under a three-year $4.2 million contract with NIAID, AFRRI, and USUHS [pipeline].
- Two regenerative aesthetic products, Regenativo+ and Placento+, completed U.S. product listings in June 2026, clearing the way for commercial launch [news · published 2026-06-02].
- As of June 30, 2026, cash & equivalents were $3.5M and shareholders' equity was -$23.0M [latest reported financials].
- Accumulated deficit reached $466,876,000 since inception in May 2001, and the company does not anticipate significant product revenues in the next twelve months [sec_mda · as of 2026-09-10].
What works
- Proprietary 3D cell-expansion platform with an in-house, industrial-scale GMP manufacturing facility provides scalable, cost-efficient, and reproducible cell production [sec_mda · as of 2026-09-10].
- PLX-R18 is supported by a three-year $4.2 million contract with U.S. government agencies (NIAID, AFRRI, USUHS), indicating external validation and non-dilutive funding [pipeline].
- Completion of U.S. product listings for Regenativo+ and Placento+ in June 2026 enables a near-term commercial launch in regenerative aesthetics [news · published 2026-06-02].
What to weigh
- Accumulated deficit of $466,876,000 and negative shareholders' equity of -$23.0M as of June 30, 2026, reflect a long history of losses [sec_mda · as of 2026-09-10] [latest reported financials].
- Cash & equivalents of only $3.5M as of June 30, 2026, may be insufficient to sustain operations without additional liquidity [latest reported financials].
- The company states it does not anticipate significant revenues from product sales in the next twelve months, and near-term revenues are unlikely to exceed operating costs [sec_mda · as of 2026-09-10].
- PLX-R18 is still in Phase 1, and the company faces risks of delays or failure in clinical trials and regulatory approval [sec · filed 2026-06-22].
From the filings
Quoted directly from source documents.
Pluri's 3D cell-expansion platform and GMP facility
“We are a biotechnology company leveraging our proprietary 3D cell expansion platform, which is supported by an in-house, industrial-scale cell manufacturing facility and operates in accordance with GMP standards on a self-declared basis.”
SEC MD&A · September 10, 2026
PLX-R18 partnership and funding
“Three-year $4.2 million contract to advance development of PLX-R18 for H-ARS”
Regenativo+ and Placento+ U.S. launch readiness
“Pluri Announces Completion Of Development And U.S. Cosmetic Product Listings For Two Flagship Regenerative Aesthetic Products, Regenativo+ And Placento+, Clearing Way For U.S. Commercial Launch”
News · June 2, 2026
Accumulated deficit and cash position
“We have accumulated a deficit of $466,876,000 since our inception in May 2001.”
SEC MD&A · September 10, 2026
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash & equivalents of $3.5M as of June 30, 2026, may be insufficient to fund operations without additional financing [latest reported financials].
- Clinical and regulatory risk — PLX-R18 is in Phase 1; delays or failure in trials or regulatory approval could derail the pipeline [sec · filed 2026-06-22].
- Revenue generation risk — Company does not anticipate significant product revenues in the next twelve months; near-term revenues unlikely to cover costs [sec_mda · as of 2026-09-10].
- Accumulated deficit — Accumulated deficit of $466.9M as of June 30, 2026, reflects sustained losses and limited profitability prospects [sec_mda · as of 2026-09-10].
What to watch
- U.S. commercial launch and initial sales of Regenativo+ and Placento+ following June 2026 product listings [news · published 2026-06-02].
- Progress of PLX-R18 Phase 1 clinical trial and any updates from the NIAID/AFRRI/USUHS collaboration [pipeline].
- Ability to secure additional liquidity to fund operations and commercialization, given the low cash balance [sec_mda · as of 2026-09-10].
- Any changes in accumulated deficit or cash position in future financial reports [sec_mda · as of 2026-09-10].
Sources: Competitor trials · News · Pipeline · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Pluri Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pluri Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
N/A
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$91K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 19,424 | $66K |
| morgan stanley | 3,076 | $10K |
| eversource wealth advisors, llc | 2,000 | $7K |
| citigroup inc | 1,360 | $5K |
| sima wealth partners, llc | 350 | $1K |
| wells fargo & company/mn | 185 | $628 |
| jpmorgan chase & co | 125 | $420 |
| sbi securities co., ltd. | 97 | $329 |
| ubs group ag | 95 | $322 |
| td waterhouse canada inc. | 93 | $312 |
Showing top 10 of 14 institutional holders of Pluri Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.0%
- Days to cover
- 4.3
- Shares short
- 20,487
- Daily short volume (Oct 12, 2026)
- 33.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLUR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pluri Inc.?
Pluri Inc. is a biotechnology company leveraging a proprietary 3D cell-expansion platform to develop cell-based products across human health, longevity, and foodtech, with a lead pipeline candidate in Phase 1 for hematopoietic indications.
What is Pluri Inc.'s lead drug candidate?
Pluri Inc.'s most advanced tracked candidate is plx-r18 (Phase 1) for Incomplete recovery following hematopoietic cell transplantation (HCT) and Hematopoietic Acute Radiation Syndrome (H-ARS).
Who is the CEO of Pluri Inc.?
Mr. Yaacov Yanay is the chief executive officer of Pluri Inc. (PLUR).
Where is Pluri Inc. headquartered?
Pluri Inc. (PLUR) is headquartered in Haifa, Israel.
What therapeutic areas does Pluri Inc. focus on?
Pluri Inc. develops therapies across Oncology, Immunology, Cardiovascular, Respiratory, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.